ACTR6

Across TCGA pan-cancer cohorts, ACTR6 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ACTR6’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ACTR6 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ACTR6 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where ACTR6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACTR6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.324	<.001	11	view →
HNSC	Male	IV	+0.207	<.001	8	view →
LSCC	Female	All	+0.205	<.001	8	view →
PDAC	Male	IV	−0.285	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ACTR6–CCRCC

Open the CCRCC breakdown →